心电图左心室劳损和左心室肥厚对主动脉瓣狭窄患者预后的影响

目的:探讨心电图左心室劳损(LV)和左心室肥厚(LVH)对无症状主动脉瓣狭窄患者预后的影响。方法:到我院治疗的主动脉瓣狭窄患者766例,心电图左心室劳损和左心室肥厚的预测值用Sokolow-Lyon(SL)电压标准和Cornell电压-时间(CVDP)标准评估,通过对其他预后协变量调整并进行评价。结果:心电图左心室劳损患者的心肌梗死的累计发生率显著高于非心电图劳损的患者(HR=2.7,95%CI:1.4-5.3,P=0.006)。与非心电图左心室肥厚的患者比较,SL标准与CVDP标准联用诊断的左心室肥厚患者心力衰竭的风险显著增加(95%CI:4.7-26.4,P0.001);行主动脉瓣置换术风险显著增加(95%CI:1.6-3.2,P0.001);非致死性梗死、心力衰竭或心血管死亡的复合终点风险也显著增加(95%CI:1.2-3.7,P0.05)。结论:心电图LV和LVH是无症状主动脉瓣狭窄患者预后不良的独立预测因子。     

Electrical Inhomogeneity in Left Ventricular Hypertrophy

Recent studies designed to assess the relationship between aortic compliance and heterogeneity of heart electrical activity has shown that hypertrophy aggravates repolarization disturbances in the myocardium. Numerous mechanisms of electrical instability and inhomogeneity associated with left ventricular hypertrophy are now under investigation. Most of the studies have been found to be focused on ventricular Gradient, QT dispersion, amplitudes of isointegral maps during ventricular repolarization, abnormally low-QRST areas, dispersion of the QT interval, and spatial QRS-T _angle. These studies point to marked repolarization abnormalities in left ventricular hypertrophy and the dispersion of the QT interval as a valuable index for inhomogeneity of repolarization and the subsequent heart rate variability. The heart rate-corrected QT dispersion and QT apex dispersion seem to be significantly longer in the patients with left ventricular hypertrophy than in normal individuals. The review study has also identified QRST isointegral map as a valuable technique in assessment of the electro-cardiac events in LVH.     

Association of Arterial Stiffness and Electrocardiography-Determined Left Ventricular Hypertrophy with Left Ventricular Diastolic Dysfunction

Objectives

Increased arterial stiffness is associated with left ventricular diastolic dysfunction (LVDD), but this association may be influenced by left ventricular (LV) performance. Left ventricular hypertrophy (LVH) is not only a significant determinant of LV performance, but is also correlated with LVDD. This study is designed to compare LV diastolic function among patients divided by brachial-ankle pulse wave velocity (baPWV) and electrocardiography (ECG)-determined LVH and to assess whether increased baPWV and ECG-determined LVH are independently associated with LVDD.

Methods

This cross-sectional study enrolled 270 patients and classified them into four groups according to the median value of baPWV and with/without ECG-determined LVH. The baPWV was measured using an ABI-form device. ECG-determined LVH was defined by Sokolow-Lyon criterion. LVDD was defined as impaired relaxation, pseudonormal, and restrictive mitral inflow patterns. Groups 1, 2, 3, and 4 were patients with lower baPWV and without ECG-determined LVH, lower baPWV but with ECG-determined LVH, higher baPWV but without ECG-determined LVH, and higher baPWV and with ECG-determined LVH respectively.

Results

Early diastolic mitral velocity (Ea) was gradually decreased from group 1 to group 4 (p≦0.027). Patients in group 4 had the highest prevalence of LVDD (all p<0.001). After multivariate analysis, both baPWV and ECG-determined LVH were independent determinants of Ea (β = −0.02, P<0.001; β = −1.77, P<0.001 respectively) and LVDD (odds ratio = 1.02, P = 0.011 and odds ratio = 3.53, P = 0.013 respectively).

Conclusion

Our study showed the group with higher baPWV and ECG-determined LVH had the lowest Ea and highest prevalence of LVDD. In addition, both baPWV and ECG-determined LVH were independently associated with Ea and LVDD. Hence, assessment of arterial stiffness by baPWV and LVH by ECG may be useful in identifying the high risk group of LVDD.     

The Relationship between Adiponectin and Left Ventricular Mass Index Varies with the Risk of Left Ventricular Hypertrophy

Background

Adiponectin directly protects against cardiac remodeling. Despite this beneficial effect, most epidemiological studies have reported a negative relationship between adiponectin level and left ventricular mass index (LVMI). However, a positive relationship has also been reported in subjects at high risk of left ventricular hypertrophy (LVH). Based on these conflicting results, we hypothesized that the relationship between serum adiponectin level and LVMI varies with the risk of LVH.

Methods

A community-based, cross-sectional study was performed on 1414 subjects. LVMI was measured by echocardiography. Log-transformed adiponectin levels (Log-ADPN) were used for the analysis.

Results

Serum adiponectin level had a biphasic distribution (an increase after a decrease) with increasing LVMI. Although Log-ADPN did not correlate with LVMI, Log-ADPN was modestly associated with LVMI in the multivariate analysis (β = 0.079, p = 0.001). The relationship between adiponectin level and LVMI was bidirectional according to the risk of LVH. In normotensive subjects younger than 50 years, Log-ADPN negatively correlated with LVMI (r = −0.204, p = 0.005); however, Log-ADPN positively correlated with LVMI in ≥50-year-old obese subjects with high arterial stiffness (r = 0.189, p = 0.030). The correlation coefficient between Log-ADPN and LVMI gradually changed from negative to positive with increasing risk factors for LVH. The risk of LVH significantly interacted with the relationship between Log-ADPN and LVMI. In the multivariate analysis, Log-ADPN was associated with LVMI in the subjects at risk of LVH; however, Log-ADPN was either not associated or negatively associated with LVMI in subjects at low risk of LVH.

Conclusion

Adiponectin level and LVMI are negatively associated in subjects at low risk of LVH and are positively associated in subjects at high risk of LVH. Therefore, the relationship between adiponectin and LVMI varies with the risk of LVH.     

ACE and AGTR1 Polymorphisms in Pathogenesis of Human Left Ventricular Hypertrophy

The A2350G polymorphism of exon 17 of the angiotensin I-converting enzyme gene (ACE) and the A1166C polymorphism of the 3-untranslated region (3-UTR) of the angiotensin II type 1 receptor gene (AGTR1) were tested for association with left ventricular hypertrophy (LVH) in patients with essential hypertension (EH) or arterial hypertension (AH) combined with diabetes mellitus type 2 (DM2). The patients with EH or AH + DM2 did not differ significantly in ACE or AGTR1 allele or genotype frequencies from healthy subjects. Both polymorphisms were associated with LVH in EH. AGTR1 allele 1166C was more frequent in patients with LVH than without (33.6 vs. 20.7%) and affected the left ventricular mass index (LVMI) in patients with EH (p = 0.007). The frequency of ACE allele 2350G in EH patients with LVH was 1.5 times higher, and that of genotype GG was 3.5 times higher, than in patients without LVH. LVMI differed significantly (p = 0.002) between patients with different ACE genotypes, being maximum in homozygotes GG and minimum in homozygotes AA. Thus, AGTR1 allele 1166C and ACE allele 2350G were identified as predisposing to LVH in EH. The two polymorphisms were not associated with the incidence or severity of LVH in patients with AH and DM2.     

Nocturnal Blood Pressure Pattern Affects Left Ventricular Remodeling and Late Gadolinium Enhancement in Patients with Hypertension and Left Ventricular Hypertrophy

Background

Left ventricular hypertrophy (LVH) is an independent predictor of cardiac mortality, regardless of its etiology. Previous studies have shown that high nocturnal blood pressure (BP) affects LV geometry in hypertensive patients. It has been suggested that continuous pressure overload affects the development of LVH, but it is unknown whether persistent pressure influences myocardial fibrosis or whether the etiology of LVH is associated with myocardial fibrosis. Comprehensive cardiac magnetic resonance (CMR) including the late gadolinium enhancement (LGE) technique can evaluate both the severity of changes in LV geometry and myocardial fibrosis. We tested the hypothesis that the nocturnal non-dipper BP pattern causes LV remodeling and fibrosis in patients with hypertension and LVH.

Methods

Forty-seven hypertensive patients with LVH evaluated by echocardiography (29 men, age 73.0±10.4 years) were examined by comprehensive CMR and 24-h ambulatory blood pressure monitoring (ABPM).

Results and Conclusions

Among the 47 patients, twenty-four had nocturnal non-dipper BP patterns. Patients with nocturnal non-dipper BP patterns had larger LV masses and scar volumes independent of etiologies than those in patients with dipper BP patterns (p = 0.035 and p = 0.015, respectively). There was no significant difference in mean 24-h systolic BP between patients with and without nocturnal dipper BP patterns (p = 0.367). Among hypertensive patients with LVH, the nocturnal non-dipper blood pressure pattern is associated with both LV remodeling and myocardial fibrosis independent of LVH etiology.     

Relationship between Serum Bilirubin and Left Ventricular Hypertrophy in Patients with Essential Hypertension

Background

Prospective studies have found low bilirubin levels were an important predictive factor of cardiovascular events. However, few have yet investigated possible association between serum bilirubin level and LVH in essential hypertension. The aim of the present study was to evaluate the relationship between serum bilirubin levels with LVH in newly diagnosed hypertension patients.

Methods

The present study evaluated the relationship between serum total bilirubin level and left ventricle hypertrophy (LVH) in newly diagnosed hypertensive patients with a sample size of 344. We divided subjects into LVH group (n=138) and non-LVH group (n=206). Physical examination, laboratory tests and echocardiography were conducted. The multivariate logistic regression model was used to verify the independent association between RDW and LVH.

Results

Our results found that patients with LVH had lower bilirubin levels than non-LVH ones. Stepwise multiple linear regression analysis showed total bilirubin level (B=-0.017, P=0.008) was negatively associated with left ventricle mass index (LVMI) even adjusting for some confounders. The multiples logistic regression found total bilirubin level was independently related with of LVH, as a protective factors (OR=0.91, P=0.010).

Conclusion

As a routine and quick laboratory examination index, serum bilirubin may be treated as novel marker for evaluating LVH risk in hypertensive patients. Cohort study with larger sample size are needed.     

Determinants of insulin-resistant phenotypes in normal-weight and obese Black African women

Objective: Subsets of metabolically “healthy obese” and “at‐risk” normal‐weight individuals have been previously identified. The aim of this study was to explore the determinants of these phenotypes in black South African (SA) women. Methods and Procedures: From a total of 103 normal‐weight (BMI ≤ 25 kg/m²) and 122 obese (BMI ≥ 30 kg/m²) black SA women, body composition, fat distribution, blood pressure, fasting glucose levels, insulin resistance, and lipid profiles were measured. Questionnaires relating to family history, physical activity energy expenditure (PAEE), and socio‐demographic variables were administered. The subjects were classified as insulin sensitive or insulin resistant according to the homeostasis model assessment of insulin resistance (HOMA‐IR) (≥1.95 insulin resistant). Results: Our study showed that 22% of the normal‐weight women were insulin resistant and 38% of the obese women were insulin sensitive. Increased visceral adipose tissue (VAT) (P = 0.001) and decreased VAT/leg fat mass (P ≤ 0.001), independent of total body fatness, distinguished between the phenotypes. Moreover, the insulin‐sensitive women were of higher socioeconomic status, did more leisure and vigorous PAEE and were less likely to use injectable contraceptives. Using a regression model, body fat distribution, percent body fat, age, log leisure PAEE, and use of injected contraception accounted for 35% of the variance in HOMA‐IR in the normal‐weight women. In the obese women, 34% of the variance in HOMA‐IR was explained by the same variables, excluding PAEE. No differences in smoking status or family history of metabolic disease were found between the phenotypes. Discussion: Central fat distribution, total adiposity, socioeconomic status, leisure PAEE, and use of injectable contraceptives distinguished between insulin‐sensitive and insulin‐resistant black SA women.     

AGT基因SNPs与哈萨克族高血压左室肥厚关系的研究

目的探讨血管紧张素原基因（angiotensinogen gene,AGT）-6A／G,-20A／C,M235T和T174M 4个单核苷酸多态性（single nucleotide polymorphisms,SNPs）与新疆哈萨克族高血压患者左室肥厚的关系。方法采用低渗溶血法破裂血细胞、蛋白酶K消化、饱和酚／氯仿抽提法提取白细胞基因组DNA。采用聚合酶链反应-限制性片断长度多态性（polymerase chain reaction—restriction fragment length polymorphism,PCR-RFLP）技术进行个体基因型分型。结果①在不考虑年龄、高血压病史时间、性别及收缩压、舒张压对左室肥厚的影响的前提下,未发现-6A／G、-20A／C与哈萨克族高血压左室肥厚的相关关系。②在以性别作为亚变量的分析结果中,我们发现-6A／G和-20A／C分别与哈萨克族女性和男性高血压左室肥厚相关。③不同SNPs间的配对连锁不平衡分析结果显示,除M235T与T174M之间外,其他各位点间存在有统计学意义的连锁不平衡关系。④单体型分析结果发现,研究人群AGT基因-6A／G、-20A／C、M235T和T174M4个SNPs构成了11种主要的单体型,其中H2（A—G—M—T）、H5（C—A—M—M）、H6（C—A-T—T）、H9（C-A—T—M）的频率在左室肥厚、非左室肥厚两组的分布存在差异,且具有统计学意义（P〈0．05）。结论AGT基因-6A／G、-20A／C、M235T和T174M变异可能与新疆哈萨克族高血压左室肥厚有关。     

促红细胞生成素对血液透析患者血浆脂联素水平及左心室肥厚的影响

目的:促红细胞生成素(EPO)在维持性血液透析患者中具有保护心血管的作用,本文旨在探讨EPO在血液透析病人中对脂联素(ADPN)水平及左心室肥厚的影响。方法:46名维持性血液透析患者用EPO治疗8周,分别在治疗前,治疗第2、4、8周后测定血红蛋白(Hb),红细胞压积(Hct),血浆白蛋白(ALB),体重指数(BMI),C反应蛋白(CRP),血清铁蛋白(SF),血清铁饱和度(TAST),ELISA测定ADPN水平;彩色多普勒超声测定左心室心肌重量(LVM)及计算左心室心肌重量指数(LVMI)。结果:血液透析患者血清ADPN水平高于正常人;用EPO治疗2周后即出现ADPN水平升高,第4周后ADPN水平进一步升高,第8周与第4周比较无明显变化;应用EPO可降低CRP、SF水平;ADPN是LVMI的重要影响因子,EPO可改善左心室肥厚与功能。结论:EPO可提高血液透析患者ADPN水平,降低CRP、SF水平,减轻左心室肥厚。     

老年高血压患者血清D-二聚体与左室肥厚的相关性研究

目的:探讨血清D-二聚体(D-D)与老年原发性高血压(EH)患者左室肥厚的相关性。方法:选取我院收治的老年EH患者158例为研究对象,均行心脏超声检查,依据左室质量指数(LVMI)将患者分为左室肥厚组(LVH组,n=72例)和非左室肥厚组(非LVH组,n=86例);分析比较两组患者血清D-D水平及相关实验室检查指标的差异。用Logistic回归模型分析血清D-D水平与左室肥厚的关系,用ROC曲线分析血清D-D水平预测老年EH患者发生左室肥厚的价值。结果:LVH组患者血清D-D水平[(315.54±45.70)μg/L]高于非LVH组[(148.29±37.65)μg/L](t=13.456,P0.05);D-D增高组患者LVMI[(137.25±16.94)g/m~2]高于非LVH组[(104.39±14.84)g/m~2](t=12.876,P0.05);D-D增高组中有发生左室肥厚的比例显著高于D-D正常组(65.1%vs 38.3%,X2=4.567,P0.05)。血清D-D与LVMI呈正相关(r=0.354,P0.05),与NT-pro BNP亦呈正相关(r=0.394,P0.05)。血清D-D水平(OR=1.239,95%CI:1.134~1.548,P0.05)是老年EH发生左室肥厚呈的独立相关因素。血清D-D预测发生左室肥厚的曲线下面积(ROCAUC)为0.879;灵敏度及特异度分别是89.8%及78.7%,最佳诊断截点为295.54μg/L。结论:老年EH患者血清D-D水平可能是左室肥厚发生的独立危险因素,血清D-D指标对于评价高EH患者左室肥厚的发生具有一定的临床意义。     

促红细胞生成素对血液透析患者血浆脂联素水平及左心室肥厚的影响

目的：促红细胞生成素（EPO）在维持性血液透析患者中具有保护心血管的作用,本文旨在探讨EPO在血液透析病人中对脂联素（ADPN）水平及左心室肥厚的影响。方法：46名维持性血液透析患者用EPO治疗8周,分别在治疗前,治疗第2、4、8周后测定血红蛋白（Hb）,红细胞压积（Hct）,血浆白蛋白（ALB）,体重指数（BMI）,C反应蛋白（CRP）,血清铁蛋白（SF）,血清铁饱和度（TAST）,ELISA测定ADPN水平;彩色多普勒超声测定左心室心肌重量（LVM）及计算左心室心肌重量指数（LVMI）。结果：血液透析患者血清ADPN水平高于正常人;用EPO治疗2周后即出现ADPN水平升高,第4周后ADPN水平进一步升高,第8周与第4周比较无明显变化;应用EPO可降低CRP、SF水平;ADPN是LVMI的重要影响因子,EPO可改善左心室肥厚与功能。结论：EPO可提高血液透析患者ADPN水平,降低CRP、SF水平,减轻左心室肥厚。     

Circulating Level of miR-378 Predicts Left Ventricular Hypertrophy in Patients with Aortic Stenosis

Aims

Excessively high left ventricle mass is an independent predictor of adverse prognosis. MicroRNAs (miRs) play crucial roles in the regulation of left ventricle hypertrophy (LVH). However, few circulating miRs have been established as predictors of LVH in aortic stenosis (AS) patients. In this study, we aimed to investigate whether circulating levels of miR-1, miR-133, and miR-378 predict LVH in patients with AS.

Methods and Results

One-hundred twelve patients with moderate to severe AS and 40 healthy controls were included in the study. Levels of miR-1, miR-133, and miR-378 in the plasma were measured by qPCR. Compared with healthy controls, AS patients had significantly lower circulating levels of miR-1, miR-133, and miR-378. AS patients with LVH had significantly lower miR-378 but not miR-1 and miR-133 compared with those without LVH. Linear regression analysis showed circulating miR-378 had strong correlation with left ventricular mass index (r = 0.283, p = 0.002) and logistic regression showed that lower miR-378 was an independent predictor for LVH in patients with AS (p = 0.037, OR 4.110, 95% CI 1.086 to 15.558).

Conclusion

Circulating levels of miR-1, miR-133 and miR-378 were decreased in AS patients, and miR-378 predicts LVH independent of the pressure gradient. Further prospective investigations are needed to elucidate whether these circulating miRs affect clinical outcome.     

The Association of Growth Differentiation Factor-15 with Left Ventricular Hypertrophy in Hypertensive Patients

Growth differentiation factor-15 (GDF-15) has been identified as an endogenous anti-hypertrophy effect. However, the association of plasma GDF-15 levels with left ventricular hypertrophy (LVH) in hypertension is poorly understood. We investigate the effect of plasma GDF-15 levels on left ventricular hypertrophy (LVH) in hypertension. We measured the plasma levels of GDF-15 in 299 untreated hypertensive patients which consisted of 99 with LVH and 200 without LVH using immunoradiometric assay. All subjects were examined by the ultrasonic cardiograph to determine Left ventricular (LV) internal diameters, septal thickness, and posterior wall thickness. The associations of GDF-15 with left ventricular mass index (LVMI), LV end-systolic and –diastolic diameters, LV wall thickness, and LV ejection fraction were evaluated. We found that plasma GDF-15 levels in hypertensive patients with LVH [median 1101, 25th–75th percentiles (879–1344) ng/L] were higher than that in hypertensive patients without LVH [median 516, 25th–75th percentiles (344–640) ng/L] (P<0.001). After adjustment for traditional covariates, plasma GDF-15 levels were independently related to LVMI (R² = 0.53; β = 0.624, P<0.001), LV interventricular septal thickness (R² = 0.23; β = 0.087, P<0.01) and LV posterior wall thickness (R² = 0.26; β = 0.103, P<0.05). Our cross-sectional data on a hospital-based sample indicate that plasma GDF-15 levels are associated with LVH in hypertensive patients.     

氯沙坦对原发性高血压患者左心室肥厚及血清MMP-9的影响

目的:探讨氯沙坦对原发性高血压伴左心室肥厚患者左心室结构及血清MMP-9的影响.方法:86例原发性高血压伴左心室肥厚患者分为氯沙坦治疗组(n=46)和对照组(n=40).在治疗前及治疗后8w,测定收缩压和舒张压,用彩色多普勒超声诊断仪测量舒张期左心室后壁厚度(PWT),舒张期室间隔厚度(IVST),左心室舒张末内径(LVID),并计算左室重量指数(LVMI)以判定左心室肥厚程度,另外,采用酶联免疫吸附法(ELISA)检测血清MMP-9.结果:治疗8w后,两组患者的收缩压、舒张压、LVMI值、血清MMP-9均较治疗前低(P<0.01或P<0.05),且氯沙坦治疗组患者的收缩压、舒张压、LVMI值、血清MMP-9较对照组低(P<0.01或P<0.05).结论:氯沙坦能降低原发性高血压血压、逆转左心室肥厚,并且能降低血清MMP-9表达.     

ET-1与NT-proBNP浓度变化对高血压左心室肥厚的诊断价值

目的:探讨高血压左心室肥厚(Left ventricular hypertrophy,LVH)患者血浆内皮素(Endothelin,ET-1)、氨基末端脑钠肽前体(N-terminal pro brain natriuretic peptide,NT-proBNP)的浓度变化及其诊断价值。方法:收集2011年3月-2013年5月我医院确诊为高血压LVH患者128例设为观察组,选取同期128例体检正常人作为对照组。分析比较两组ET-1、NT-proBNP的浓度。结果:观察组血浆NT-proBNP及ET-1浓度分别为(6.4±3.5)pg/m L和(18.4±1.5)pg/m L,显著高于对照组,差异有统计学意义(P0.05);ROC图显示,NT-proBNP曲线下面积为0.932,可信区间为0.886-0.988,灵敏度为97.8%,特异度为79.9%;血浆ET-1曲线下面积为0.798,可信区间为0.709-0.892,灵敏度为65%,特异度为93.1%。结论:高血压LVH患者NT-proBNP及血浆ET-1水平显著高于正常人,对高血压LVH患者NT-proBNP及血浆ET-1的诊断具有重要意义。     

Delayed Treatment Effects of Xanthine Oxidase Inhibition on Systolic Overload-Induced Left Ventricular Hypertrophy and Dysfunction

The nonpurine selective xanthine oxidase (XO) inhibitor febuxostat attenuates development of left ventricular (LV) hypertrophy and dysfunction in mice when treatment is initiated within 1 hour of transverse aortic constriction (TAC). This study investigated whether a 7-day delay of treatment with the XO inhibitors febuxostat or allopurinol would reverse TAC-induced changes after onset of heart failure (HF). Neither treatment significantly affected TAC-induced LV hypertrophy; only febuxostat caused a modest improvement in LV function (～10% increase in LV ejection fraction). However, the purine analog allopurinol tended to increase mortality compared with vehicle or febuxostat in HF mice.     

Left Ventricular Hypertrophy Is Associated With Obesity,Male Gender,and Symptoms in Healthy Adolescents

Obesity has been found to be associated with left ventricular (LV) hypertrophy (LVH). However, the occurrence of LVH in obese teenagers who are involved in sport programs has not been studied. The objective of this study was to evaluate the prevalence of LVH and its correlation with obesity, gender, and symptoms in teenage athletes. We used echocardiographic database of 1,500 adolescences between the ages of 12 and 20 years who were actively involved in school sport programs. We evaluated associations between obesity and LVH (defined as LV wall thickness (LVWT)) >12 mm, or LV mass (LVM) >215 g or relative wall thickness (RWT) >0.43) and physical symptoms. Using univariate and multivariate analysis, male gender was associated with increased LVWT (multivariate odds ratio (OR) 4.87, confidence interval (CI) 2.41–9.82). Obesity was associated with parameters of LVH using univariate and multivariate analysis. (LVM > 215 g) occurred in 10.32% of obese athletes vs. 0.2% (1/445) of controls, (OR 51.33, CI 6.05–433.8), P < 0.001, LVWT >12 mm occurred in 16.5% of obese students vs. 3.6% of controls (OR 5.2, CI 2.7–10.1, P < 0.001), RWT >0.43 occurred in 41.4% of obese students vs. 15.7% of controls (OR 3.78, CI 2.11–6.76, P < 0.001). After adjusting for age and gender, reported history of shortness of breath (SOB), fatigue and leg edema were also significantly more prevalent in obese students and in students with LVH. In conclusion obesity is associated with LVH in a population of healthy teenagers actively involved in sport programs. Furthermore, the presence of LVH was independently associated with many physical symptoms suggesting negative effect of LVH on myocardial function.